

Application No. 09/986,234  
Amendment dated February 22, 2005

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1 (Canceled).

2 (Currently amended): The method isolated nucleic acid of claim 341, wherein said mammalian resistin, or fragment thereof, is encoded by a nucleic acid that shares at least about 30% sequence identity with an nucleic acid encoding at least one of mouse resistin (SEQ ID NO:1) and human resistin (SEQ ID NO:3).

3 (Currently amended): The method isolated nucleic acid of claim 2, wherein said mammalian resistin, or fragment thereof, is encoded by a nucleic acid that shares at least about 30% sequence identity with a nucleic acid having the sequence of SEQ ID NO:1.

4 (Currently amended): The method isolated nucleic acid of claim 2, wherein said mammalian resistin, or fragment thereof, is encoded by a nucleic acid that shares at least about 30% sequence identity with a nucleic acid having the sequence of SEQ ID NO:3.

5-8 (Canceled).

9 (Currently amended): The method isolated polypeptide of claim 348, wherein said mammalian resistin shares at least about 30% sequence identity with an amino acid sequence of at least one of SEQ ID NO: 2 and SEQ ID NO:4.

Application No. 09/986,234  
Amendment dated February 22, 2005

10 (Currently amended): The method ~~isolated polypeptide of claim 349~~, wherein said mammalian resistin shares at least about 30% sequence identity with an amino acid sequence of SEQ ID NO:2.

11 (Currently amended): The method ~~isolated polypeptide of claim 349~~, wherein said mammalian resistin shares at least about 30% sequence identity with an amino acid sequence of SEQ ID NO:4.

12-22 (Canceled).

23 (Currently amended): The method ~~antibody of claim 3422~~, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, and a synthetic antibody.

24 (Currently amended): The method of claim 34, wherein said ~~An antidiabetic composition further comprises comprising the antibody of claim 22 and a~~ pharmaceutically-acceptable carrier.

25-33 (Canceled).

34 (Currently amended): A method of treating or alleviating type 2 diabetes, said method comprising administering to a patient afflicted with type 2 diabetes an a-glucose uptake enhancing amount of the composition of claim 24 a composition comprising an antibody that specifically binds with a mammalian resistin polypeptide, or fragment thereof, and a pharmaceutically acceptable carrier.

35-81 (Canceled).

Application No. 09/986,234  
Amendment dated February 22, 2005

82 (New): The method according to claim 34, wherein said amount enhances glucose uptake in said patient.

83 (New): The method according to claim 34, wherein said amount inhibits production/expression of resistin in said patient.